Israel - English - Ministry of Health

teva israel ltd - gabapentin - capsules - gabapentin 400 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - capsules - gabapentin 400 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 600 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 800 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Israel - English - Ministry of Health

teva israel ltd - calcium folinate - tablets - calcium folinate 16.2 mg - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency.

Israel - English - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - tadalafil - film coated tablet - 20 milligram - drugs used in erectile dysfuntion - urologicals, drugs used in erectile dysfunction - treatment of erectile dysfunction in adult males. in order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required. tadalafil teva is not indicated for use by women.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline - anti-parkinson-drugs, monoamine oxidase -b inhibitors - rasagiline teva is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - imatinib mesilate, quantity: 477.877 mg (equivalent: imatinib, qty 400 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - imatinib mesilate, quantity: 477.877 mg (equivalent: imatinib, qty 400 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).